Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01272219 · ClinicalTrials.gov registry record · Phase 3

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

A Phase 3 study of Obesity and Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 3
Development phase
3,731
Enrollment target
20
Study locations

NCT01272219: Completed Phase 3 study of Obesity and Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.

NCT01272219 is a Phase 3 study of Obesity and Metabolism and Nutrition Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 3,731 participants, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (358% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01272219, a Phase 3 study of Obesity and Metabolism and Nutrition Disorder, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 3
Development phase
3,731 participants
Enrollment target
20
Study locations

Study Summary

This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline. Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).

Primary Outcome

The observed mean change from baseline in fasting body weight (%) after 56-weeks of treatment (main treatment period).

Conditions Studied

Obesity Metabolism and Nutrition Disorder

Interventions

  • DRUG placebo
  • DRUG liraglutide

Study Locations (20)

California

  • Novo Nordisk Investigational Site - Anaheim
  • Novo Nordisk Investigational Site - Concord
  • Novo Nordisk Investigational Site - Huntington Beach
  • Novo Nordisk Investigational Site - La Jolla
  • Novo Nordisk Investigational Site - San Diego
  • Novo Nordisk Investigational Site - San Diego
  • Novo Nordisk Investigational Site - Santa Monica

Florida

  • Novo Nordisk Investigational Site - Boynton Beach
  • Novo Nordisk Investigational Site - Bradenton
  • Novo Nordisk Investigational Site - Crystal River
  • Novo Nordisk Investigational Site - Daytona Beach
  • Novo Nordisk Investigational Site - Jacksonville

Colorado

  • Novo Nordisk Investigational Site - Aurora
  • Novo Nordisk Investigational Site - Colorado Springs
  • Novo Nordisk Investigational Site - Golden

Connecticut

  • Novo Nordisk Investigational Site - New London
  • Novo Nordisk Investigational Site - Waterbury

Alabama

  • Novo Nordisk Investigational Site - Birmingham

Arizona

  • Novo Nordisk Investigational Site - Phoenix

District of Columbia

  • Novo Nordisk Investigational Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 3,731 participants
Start Date 2011-06-01
Est. Completion 2015-03-02
Phase Phase 3
Novo Nordisk A/S

431 total trials

What the finished NCT01272219 record still lists

NCT01272219 is an interventional study that assigns participants to a tested intervention. Its 3,731 participants enrollment target places it among the larger protocols in the corpus, above the 815-participant average among 1,053 other Obesity trials with a reported enrollment target (358% higher).

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01272219 names 20 study sites across 7 states, led by California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT01272219 about?

NCT01272219 is a clinical study titled "Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes". This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim i...

What is the current status of trial NCT01272219?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,731 participants. The study started on 2011-06-01. Estimated completion is 2015-03-02.

What conditions does trial NCT01272219 study?

This clinical trial studies the following conditions: Obesity, Metabolism and Nutrition Disorder.

What interventions are being tested in trial NCT01272219?

The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).

Who is sponsoring clinical trial NCT01272219?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01272219 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01272219's enrollment target sits among peer trials

3,731 28th of 1053 higher than 1,026 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06076304 · 3,720 participants · Phase 4

    Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

  • NCT06172660 · 3,750 participants

    Real-World Effectiveness of Perinatal RSV Immunoprophylaxis

  • NCT06298253 · 3,750 participants · NA

    Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2

  • NCT06401863 · 3,691 participants · NA

    Shared Decision for Drug Interactions in Oral Anticoagulation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT01272219, the US trial registry maintained by the National Library of Medicine. NCT01272219 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.